CHClemens Höbaus

Clemens Höbaus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Clemens Höbaus has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Individual and group reflection in lecture-based large groups lead to comparable learning success

    by Clemens Höbaus, Ralf Schmidmaier

    Summary: Objective: The study aims to elucidate a possible effect of individual reflection (IR) or group reflection (GR) on short-term and long-term memory retention in a large group lecture-based environment. Methods: In this quasi-experimental study 656 medical students were enrolled to compare the impact of IR and GR directly after the lectures and 2 months later. Students were divided into two groups and given two different lectures using IR or GR in a cross-over fashion. Memory retention was estimated using multiple-choice questions analyzed by Student’s T‑test. Results: Memory retention was similar using both reflection methods at baseline ( p = 0.867; p = 0.971) and follow-up ( p = 0.885; p = 0.945). Interestingly, both reflection methods fostered good memory retention over time. Studentsʼ self-assessment initially favored GR as more beneficial, an effect that faded over time. Conclusion: Reflection might be a promising tool to foster memory retention in large lecture cohorts without added benefit from social interaction.

  • Open Access

    FGF-23 and Long-term Outcome in Peripheral Artery Disease

    by Bernhard Zierfuss, Marija Bojic, Gerit-Holger Schernthaner, Clemens Höbaus

    Atherosclerotic peripheral artery disease (PAD) and chronic kidney disease (CKD) are highly interconnected diseases, while causes for excess mortality are not well-defined. Fibroblast growth-factor 23 (FGF-23) is elevated in mineral bone disease of CKD and was shown to be associated with higher mortality. However, it is not known if this association extends to PAD. FGF-23 was measured by ELISA in serum samples of 298 patients with stable PAD (Fontaine stage I-II) with an estimated glomerular filtration rate (eGFR) of 72 (58–85) ml/min. Mortality was assessed after a long-term follow-up of up to 10 years. FGF-23 showed significant associations with markers of metabolic syndrome (triglycerides r = .25, P < .001, high-density lipoprotein cholesterol (HDL-C) r = −.28, P < .001, c-reactive protein (CRP) r = .14, P = .016). Multivariable Cox-regression outcome analyses showed significant associations between FGF-23 and all-cause mortality (hazard ratio 1.35, 95% confidence interval 1.05–1.74) in PAD patients even after adjustment for traditional cardiovascular risk factors and renal excretory function. FGF-23 is associated with higher mortality in patients with PAD. Our findings indicate that FGF-23 has detrimental effects on patients with PAD that are independent of renal excretory function.


  • Open Access

    Prevalence of extracranial carotid artery disease in symptomatic peripheral artery disease and implications for long-term outcome

    by Bernhard Zierfuss, Ladislaja Witt-Dörring, Anna Ceschi a Santa Croce, Antonia Hannes, Moritz Staudacher, Gerfried Pesau, Oliver Schlager, Michael Gschwandtner, Gerit-Holger Schernthaner, Clemens Höbaus

    Patients with peripheral artery disease (PAD) still experience excessive rates of fatal cardiovascular events. In this context, the relevance of co-existing extracranial carotid artery disease (ECAD) on outcome in patients with PAD is unclear. Thus, this study elucidates long-term outcome effects of the presence of both atherosclerotic entities for further risk stratification. A total of 669 patients from the Lip-LEAD study with symptomatic PAD (Fontaine stage 2-4) were evaluated for ECAD (internal carotid artery stenosis >50%) with ultrasonography within 6 months after endovascular repair for PAD. Outcome was assessed with a long-term follow-up period with a maximum of 10 years. Patients presenting with ECAD (n = 245, 36.7%) exhibited worse hemodynamic parameters of PAD than those without (ankle-brachial index (ABI). (0.53 (0.37-0.68) vs. 0.57 (0.47-0.68), p = 0.009; toe-brachial index (TBI) (0.50 (0.36-0.63) vs. 0.55 (0.42-0.70), p = 0.005). Significant correlations between grade of carotid stenosis and ABI as well as TBI were present (r=-0.190, p < 0.001; r=-0.219, p < 0.001). Cox-regression analyses revealed worse outcome in patients with ECAD for both all-cause and cardiovascular (CV)-mortality after multivariable adjustment for traditional CV risk-factors [1.48 (2.02-2.17); 2.10 (1.19-3.69)]. Patients with additional ECAD to symptomatic PAD exhibited an unfavourable long-term outcome in comparison to those without. The results suggest that the additional presence of ECAD highlights a highly vulnerable cohort of patients with symptomatic PAD at risk for further fatal CV events and thus should be considered for further diagnostic evaluation and stronger risk modification initiatives.


  • Letter: Answer to “Trefoil Factor-3 and Peripheral Artery Disease: Reason or Result”

    by Gerfried Pesau, Bernhard Zierfuss, Clemens Hoebaus, Renate Koppensteiner, Gerit-Holger Schernthaner

  • Open Access

    Urinary vanin-1 as a novel biomarker for survival in peripheral artery disease

    by Bernhard Zierfuss, Anna Karlinger, Marija Bojic, Renate Koppensteiner, Gerit-Holger Schernthaner, Clemens Höbaus

    Background: Chronic kidney disease is associated with increased rates of incidence, morbidity, and mortality in lower-extremity peripheral artery disease (PAD). No specific marker for a functional risk assessment of kidney disease in PAD is known, especially at the early stages. Thus, we speculated that urinary vanin-1 (uVNN1), a marker of oxidative stress even in early kidney injury, could further stratify outcome assessment in patients with PAD. Methods: Patients with stable PAD ( n = 304) of the Vienna medical cohort were followed up for up to 10 years and the outcome was assessed by central death database queries. uVNN1 was measured by enzyme-linked immunosorbent assay (ELISA) at study inclusion and normalized to urinary creatinine (uVNN1/Cr). During the observation time (9.3, 7.0–9.8 years), 104 patients died, 54.8% of which were due to cardiovascular causes. Results: uVNN1/Cr was associated with a urine albumin–creatinine ratio (UACR) ( R = 0.166, p = 0.004) but not with an estimated glomerular filtration rate ( R = 0.102, p = 0.077). Levels of uVNN1/Cr did not differ between asymptomatic and symptomatic PAD ( p = 0.406). Kaplan–Meier curves showed a clear-cut association with higher all-cause (log-rank p = 0.034) and cardiovascular mortality (log-rank p = 0.032) with higher uVNN1/Cr levels. Similarly, significant associations for all-cause (hazard ratio [HR] 1.34, 95% CI [1.08–1.67], p = 0.009) and cardiovascular mortality (HR 1.45, 95% CI [1.06–1.99], p = 0.020) could be seen in multivariable Cox regression models. Conclusions: uVNN1/Cr showed an independent association with both all-cause and cardiovascular mortality in patients with PAD and was associated with early kidney disease. Thus, uVNN1 could be a useful marker for risk stratification of kidney disease in PAD.


  • Open Access

    Serum Trefoil Factor-3 Predicts Survival in Peripheral Artery Disease

    by Gerfried Pesau, Bernhard Zierfuss, Clemens Hoebaus, Renate Koppensteiner, Gerit-Holger Schernthaner

    Trefoil factor 3 (TFF3) has been studied in processes leading to atherosclerosis. Data are scarce in manifest disease and missing in peripheral artery disease (PAD). This study aims to elucidate TFF3 with disease stages, degrees of atherosclerosis, and outcomes. TFF3 was measured in serum in 364 PAD patients without critical limb ischemia and mild to moderate chronic kidney disease (CKD). Mortality data were retrieved from the Austrian central death registry (median observation 9.6 years). Survival analyses were performed using Cox regression and the Kaplan–Meier method. A negative association between ankle-brachial index and TFF3 ( P < .001) was observed, while levels were similar in asymptomatic and symptomatic PAD. TFF3 increased with history of cardiovascular and cerebrovascular disease ( P < .001). TTF3 was associated with the estimated glomerular filtration rate (R = −0.617, P < .001) and urinary albumin-creatinine ratio (R = 0.229, P < .001). One SD increase in TFF3 showed a worsening in all-cause mortality (hazard ratio 1.68, CI 1.37–2.05) which persisted after multiple adjustment for cardiovascular risk, inflammatory, and angiogenetic markers (hazard ratio 1.35, CI 1.01–1.81). This study is the first to link TFF3 with both disease markers and outcomes in PAD. TFF3 demonstrated associations with renal function, PAD severity measured by ankle-brachial index, and additional atherosclerotic burden in PAD.


  • High-Density Lipoprotein Particle Subclasses in Statin-Treated Patients with Peripheral Artery Disease Predict Long-Term Survival

    by Bernhard Zierfuss, Clemens Höbaus, Carsten Thilo Herz, Renate Koppensteiner, Herbert Stangl, Gerit-Holger Schernthaner

    Low-density lipoprotein-cholesterol reduction showed a strong reduction of cardiovascular (CV) event rates in CV disease. However, the residual risk of future CV events remains high, which especially extends to peripheral arterial disease (PAD). Nuclear magnetic resonance (NMR) spectroscopy offers a novel method for analysis of the lipoprotein spectrum. This study investigates lipoprotein subclasses using NMR spectroscopy and assesses implications for long-term survival in PAD. NMR spectroscopy was performed by Nightingale Inc., in 319 patients with stable PAD and well-controlled CV risk factors. Patients were followed-up for 10 years. During that period, 123 patients (38.5%) died, of those 68 (21.3%) were defined as CV deaths. Outcome data were analyzed by the Kaplan–Meier method and multivariable Cox-regression for lipoprotein particles. Small and medium high-density lipoprotein-particles (S-HDL-P and M-HDL-P) showed a significant inverse association with all-cause mortality in Cox-regression analyses after multivariable adjustment (S-HDL-P, hazard ratio [HR]: 0.71, 95% confidence interval [CI]: 0.57–0.88; M-HDL-P, HR: 0.72, 95% CI: 0.58–0.90) for each increase of one standard deviation. In contrast, cholesterol-rich X-large HDL-particles (XL-HDL-P) showed a positive association with all-cause mortality (HR: 1.51, 95% CI: 1.20–1.89). Only the association between XL-HDL-P and CV death sustained multivariable adjustment (HR: 1.49, 95% CI: 1.10–2.02), whereas associations for S-HDL-P and M-HDL-P were attenuated (HR: 0.76, 95% CI: 0.57–1.01; HR: 0.80, 95% CI: 0.60–1.06). This study shows a novel association for a beneficial role of S-HDL-P and M-HDL-P but a negative association with higher cholesterol-rich XL-HDL-P for long-term outcome in well-treated patients with PAD. Thus, these results provide evidence that NMR-measured HDL particles identify patients at high CV residual risk beyond adequate lipid-lowering therapy.


  • Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?

    by Pavel Poredoš, Renata Cífková, Jeanette Anne Marie Maier, Janos Nemcsik, Mišo Šabovič, Borut Jug, Mateja Kaja Ježovnik, Gerit Holger Schernthaner, Pier Luigi Antignani, Mariella Catalano, et al.